Drug
Intravitreal anti-VEGF injection
Intravitreal anti-VEGF injection is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_3
1
33%
Ph phase_4
1
33%
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)
Trials by Status
unknown133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular Degeneration
NCT05604989
unknownnot_applicable
"Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" Study
NCT02960828
completedphase_4
Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
NCT02471651
Clinical Trials (3)
Showing 3 of 3 trials
NCT05604989Phase 3
Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular Degeneration
NCT02960828Not Applicable
"Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" Study
NCT02471651Phase 4
Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3